Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

被引：0
|
作者：
Oliver Kummer
Felix Hammann
Claudine Moser
Olivier Schaller
Jürgen Drewe
Stephan Krähenbühl
机构：
[1] University Hospital,Division of Clinical Pharmacology and Toxicology, Department of Biomedicine
[2] Mundipharma Medical Company,undefined
来源：
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词：
Oxycodone; Ketoconazole; Paroxetine; Drug interactions; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 71
页数：8
相关论文
共 50 条
  • [31] Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
    Belle, DJ
    Ernest, CS
    Sauer, JM
    Smith, BR
    Thomasson, HR
    Witcher, JW
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1219 - 1227
  • [32] Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population
    Mutawi, Thuraya M.
    Zedan, Mohamed M.
    Yahya, Raida S.
    Zakria, Mahmoud M.
    El-Sawi, Mamdouh R.
    Gaedigk, Andrea
    PHARMACOGENOMICS, 2021, 22 (06) : 323 - 334
  • [33] Aloe Vera Juice: IC50 and Dual Mechanistic Inhibition of CYP3A4 and CYP2D6
    Djuv, Ane
    Nilsen, Odd Georg
    PHYTOTHERAPY RESEARCH, 2012, 26 (03) : 445 - 451
  • [34] Comparison of metasite and stardrop prediction of CYP3A4, CYP2C9 and CYP2D6
    Gopaul, V. Sashi
    Shin, Young
    Le, Hoa
    Baumgardner, Matthew
    Hop, Cornelis
    Khojasteh, Cyrus
    DRUG METABOLISM REVIEWS, 2009, 41 : 119 - 119
  • [35] Systematic and Quantitative Assessment of the Effect of Chronic Kidney Disease on CYP2D6 and CYP3A4/5
    Yoshida, K.
    Sun, B.
    Zhang, L.
    Zhao, P.
    Abernethy, D. R.
    Nolin, T. D.
    Rostami-Hodjegan, A.
    Zineh, I.
    Huang, S-M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (01) : 75 - 87
  • [36] Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6
    Pandit, Subrata
    Mukherjee, Pulok K.
    Ponnusankar, Sivasankaran
    Venkatesh, Murugan
    Srikanth, N.
    FITOTERAPIA, 2011, 82 (03) : 369 - 374
  • [37] CHRONIC MODULATION OF CYP2D6 AND CYP3A4 ACTIVITIES BY QUINIDINE AND RIFAMPICIN RESPECTIVELY
    ADEDOYIN, A
    MAURO, K
    KUBISTY, C
    BOYER, A
    PORTER, J
    BRANCH, RA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 210 - 210
  • [38] Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin
    Al-Jenoobi, Fahad I.
    Al-Thukair, Areej A.
    Alam, Mohd Aftab
    Abbas, Fawkeya A.
    Al-Mohizea, Abdullah M.
    Alkharfy, Khalid M.
    Al-Suwayeh, Saleh A.
    SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (06) : 564 - 569
  • [39] Development and Validation of HPLC Methods for the Determination of CYP2D6 and CYP3A4 Activities
    Pan, Yan
    Mak, Joon Wah
    Ong, Chin Eng
    CURRENT PHARMACEUTICAL ANALYSIS, 2012, 8 (03) : 219 - 224
  • [40] Probabilistic prediction of the human CYP3A4 and CYP2D6 metabolism sites in a molecule
    Dapkunas, Justas
    Sazonovas, Andrius
    Japertas, Pranas
    TOXICOLOGY LETTERS, 2008, 180 : S94 - S94
12345